The relationship between metabolic syndrome severity and the risk of mortality in gout patients: a population-based study
N. Schlesinger1, M.I. Elsaid2, V.K. Rustgi3
- Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. firstname.lastname@example.org
- Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA.
- Center for Liver Diseases and Liver Masses, Division of Gastroenterology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
2022 Vol.40, N°3
PI 0631, PF 0633
Free to view
(click on article PDF icon to read the article)
PMID: 35238754 [PubMed]
Accepted : 17/12/2021
In Press: 01/02/2022
To examine Metabolic Syndrome (MetS) severity using a recently validated Metabolic Syndrome Severity Score (MetSSS) in order to explore the overall associations between MetSSS and the risk of mortality related to all-causes, heart disease, diabetes mellitus, and hypertension amongst American adults with gout.
Mortality-linked data for 12,101 adults aged 18 to 90 years who participated in the National Health and Nutrition Examination Survey III by gout status was analysed. All 5 metabolic features were used to calculate gender-race/ethnicity-specific MetSSS Z-scores in gout patients. The calculated Z-scores are a continuous representation of all MetS conditions while accounting for gender-race/ethnicity disparities.
A total of 3,381 deaths were observed, of which 215 had gout. The prevalence amongst adults was 2.59%. Moderate to high MetS severity was significantly prevalent amongst gout patients (47.33% vs. 21.16 % no gout; p-value <0.0001). The mean MetSSS Zscore for gout patients was significantly higher than those without gout (0.71 vs. -0.04 no gout; p-value <0.0001). A one-unit increase in MetSSS score was associated with significant increases in the risk of all-cause mortality, heart disease, diabetes- and hypertension-related mortalities.
Moderate to high MetSSS is significantly prevalent amongst gout patients. A one-unit increase in MetSSS score was associated with significant increases in the risk of all-cause mortality, heart disease, diabetes- and hypertension-related mortalities. MetS is a clinically accessible tool for predicting mortality risks in gout patients with MetS.